Table 1.
Patient demographics and baseline characteristics
| 50 mg | 100 mg | 200 mg | 300 mg | 400 mg | Total | |
|---|---|---|---|---|---|---|
| Characteristics | (n = 6) | (n = 9) | (n = 16) | (n = 51) | (n = 20) | (n = 102) |
| Age | ||||||
| Median | 48.5 | 60.0 | 60.5 | 62.0 | 53.5 | 59.0 |
| Min, max | 36, 72 | 48, 83 | 36, 83 | 32, 82 | 47, 85 | 32, 85 |
| Gender, n (%) | ||||||
| Female | 5 (83.3) | 5 (55.6) | 11 (68.8) | 26 (51.0) | 10 (50.0) | 57 (55.9) |
| Male | 1 (16.7) | 4 (44.4) | 5 (31.3) | 25 (49.0) | 10 (50.0) | 45 (44.1) |
| Race, n (%) | ||||||
| Asian | 5 (83.3) | 8 (88.9) | 15 (93.8) | 40 (78.4) | 17 (85.0) | 85 (83.3) |
| White | 1 (16.7) | 1 (11.1) | 1 (6.3) | 11 (21.6) | 3 (15.0) | 17 (16.7) |
| Baseline ECOG, n (%) | ||||||
| 0 | 5 (83.3) | 2 (22.2) | 11 (68.8) | 15 (29.4) | 5 (25.0) | 38 (37.3) |
| 1 | 1 (16.7) | 6 (66.7) | 5 (31.3) | 36 (70.6) | 15 (75.0) | 63 (61.8) |
| 2 | 0 (0.0) | 1 (11.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (1.0) |
| Baseline BM, n (%) | ||||||
| Yes | 2 (33.3) | 4 (44.4) | 4 (25.0) | 25 (49.0) | 9 (45.0) | 44 (43.1) |
| No | 4 (66.7) | 5 (55.6) | 12 (75.0) | 26 (51.0) | 11 (55.0) | 58 (56.9) |
| Number of prior cancer therapies | ||||||
| Median | 3.0 | 3.0 | 1.5 | 2.0 | 2.5 | 3.0 |
| Min, max | 1, 5 | 2, 6 | 1, 6 | 1, 10 | 1, 8 | 1, 10 |
| Mutation types, n (%) | ||||||
| EGFRexon20ins | 3 (50.0) | 2 (22.2) | 11 (68.8) | 36 (70.6) | 10 (50.0) | 62 (60.8) |
| EGFR sensitizing mutation | 0 (0.0) | 1 (11.1) | 1 (6.3) | 0 (0.0) | 2 (10.0) | 4 (3.9) |
| EGFR T790M | 0 (0.0) | 0 (0.0) | 1 (6.3) | 0 (0.0) | 0 (0.0) | 1 (1.0) |
| EGFR double mutation | 2 (33.3) | 2 (22.2) | 0 (0.0) | 2 (3.9) | 0 (0.0) | 6 (5.9) |
| HER2exon20ins | 1 (16.7) | 4 (44.4) | 3 (18.8) | 12 (23.5) | 8 (40.0) | 28 (27.5) |
| EGFR uncommon mutation | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.0) | 0 (0.0) | 1 (1.0) |
NOTE: Pooled analysis from WU-KONG1 and WU-KONG2 studies. Data cutoff date: April 3, 2021.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.